Superiority of Docetaxel plus Capecitabine Compared to Docetaxel plus Epirubicin as First-Line Therapy for Metastatic Breast Cancer - Final Results of the ERASME-4 Study.

被引：0
|
作者：
Bachelot, T.
Bajard, A.
Ray-Coquard, I
Coeffic, D.
Dramais, D.
Ferri-Dessens, R.-M.
Guastalla, J.-P.
Perol, D.
机构：
[1] Ctr Leon Berard, F-69373 Lyon, France
[2] Ctr Hosp, Annecy, France
[3] Inst Daniel Hollard, Grenoble, France
[4] Ctr Hosp, Valence, France
[5] Roche France, Paris, France
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：625S / 625S
页数：1
相关论文
共 50 条
  • [1] Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer
    Bachelot, Thomas
    Bajard, Agathe
    Ray-Coquard, Isabelle
    Provencal, Jocelyne
    Coeffic, David
    Agostini, Cecile
    Boisseau, Martial
    Kaphan, Regis
    Dramais, Dominique
    Oprea, Corina
    Ferri-Dessens, Rose-Marie
    Guastalla, Jean-Paul
    Perol, David
    ONCOLOGY, 2011, 80 (3-4) : 262 - 268
  • [2] Randomized trial of first-line docetaxel plus capecitabine (XT) versus docetaxel plus epirubicin (ET) for metastatic breast cancer (MBC): Efficacy results of ERASME-4/CAPEDOC-EPIDOC
    Bachelot, T.
    Luporsi, E.
    Bajard, A.
    Provencal, J.
    Coefic, D.
    Platini, C.
    Dramais, D.
    Oprea, C.
    Ferri-Dessens, R.
    Perol, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: Phase II results
    Gennatas, C. G.
    Michalaki, V.
    Gennatas, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    T Gamucci
    A M D'Ottavio
    E Magnolfi
    M Barduagni
    A Vaccaro
    I Sperduti
    L Moscetti
    F Belli
    L Meliffi
    British Journal of Cancer, 2007, 97 : 1040 - 1045
  • [5] Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
    Gamucci, T.
    D'Ottavio, A. M.
    Magnolfi, E.
    Barduagni, M.
    Vaccaro, A.
    Sperduti, I.
    Moscetti, L.
    Belli, F.
    Meliffi, L.
    BRITISH JOURNAL OF CANCER, 2007, 97 (08) : 1040 - 1045
  • [6] Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, Vasiliki
    Gennatas, Spyridon
    Gennatas, Konstantine
    ANTI-CANCER DRUGS, 2009, 20 (03) : 204 - 207
  • [7] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [8] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Syrigos, K.
    Kakolyris, S.
    Ziras, N.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54
  • [9] Safety and efficacy of the combination of trastuzumab plus capecitabine and docetaxel as first-line therapy for metastatic breast cancer: phase II results
    Michalaki, V.
    Gennatas, S.
    Gennatas, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 276 - 276
  • [10] Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
    Wardley, Andrew M.
    Pivot, Xavier
    Morales-Vasquez, Flavia
    Zetina, Luis M.
    Dias Gaui, Maria de Fatima
    Reyes, Douglas Otero
    Jassem, Jacek
    Barton, Claire
    Button, Peter
    Hersberger, Veronica
    Torres, Antonio Anton
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) : 976 - 983
12345